4P-Pharma and Qingdao Marine Biomedical Research Institute (QMBRI) have decided to combine their expertise to jointly develop their first-in-class drug candidates in China and Europe through the signature of a Memorandum of Understanding (MoU) to deal with their respective molecules.
“[…] It is our ambition to create a fruitful and long-term partnership for our two countries and patients worldwide”, said Dali Zhang, Vice-President of QMBRI.
“We are very pleased to build this partnership with QMBRI’s team. […]”, said Revital Rattenbach, Chairwoman of 4P-Pharma and 4Moving Biotech. “We strongly believe that our combining work will definitely benefit to Chinese, European and worldwide patients.”
“[…] I am especially happy of QMBRI and 4P-Pharma’s partnership”, said Mr. Daowen Du, European director of ICCIC-Gung Ho. “The possibility to provide a quick access of repositioning drugs, whose benefit/risk ratio has been positively proved, to the largest number of people is particularly important for China. We welcome very strongly 4P-Pharma’s expertise to guarantee Chinese drug candidates’ arrival in Europe.”
Read the full press release:
EN: 20210916_PR_MOU_QMBRI_EN
Press contact 4P-Pharma
Roselina Lam, Business Development and Licensing Manager
E-mail: roselina@4p-pharma.com